Chembio Diagnostics (PINKSHEETS: CEMI) is a leading developer, manufacturer, licensor, and marketer of point-of-care diagnostic tests for infectious diseases. The company’s two FDA PMA-approved CLIA-waived rapid HIV tests are marketed in the United States by Alere North America, Inc., and the company markets its HIV STAT-PAK line of rapid HIV tests internationally. The Dual Path Platform technology, Chembio’s patented point-of-care test platform technology, is providing the company with a substantial pipeline of business opportunities. For more information, visit the company’s Web site at www.chembio.com

B. Riley & Co. provides a full array of corporate finance, research, sales, trading, and otcqx dad services to corporate, institutional, and high net worth clients.  Headquartered in Los Angeles, with offices in San Francisco, New York, and Newport Beach, the firm is recognized for its distinguished equity research, merger and acquisitions advisory services, initial and secondary public offerings, and institutional private placements. For more information on B. Riley & Co., visit www.brileyco.com

Let us hear your thoughts below: